Skip to main content
TipRanks
Go Ultimate75% OFF

Modern Chinese Medicine Group Co. Ltd. (1643) AI Stock Analysis

0 Followers
HK:1643

Modern Chinese Medicine Group Co. Ltd.

(HKEX:1643)

Select Model
Rating:45Neutral
Price Target:HKD 0.38▼(-20.21% Downside)
Action:reiterated
Date:11/13/26

The score is primarily constrained by deteriorating profitability, revenue contraction, and weak cash generation. A conservative balance sheet provides support, but subdued technical momentum and a negative earnings-based valuation indicate substantial ongoing risk.

Positive Factors
Very Low LeverageExtremely low leverage reduces solvency risk and limits interest-related pressure on earnings. A stable asset and equity base also gives the company financial flexibility to withstand operating weakness, fund products, or pursue recovery initiatives without relying heavily on additional borrowing.
Negative Factors
Sustained Revenue DeclineA multi-year revenue contraction indicates weakening demand, distribution reach, or product mix rather than a single-period fluctuation. Continued top-line erosion reduces operating scale, makes fixed costs harder to absorb, and limits the company’s ability to restore historical profitability without renewed sales growth.

Modern Chinese Medicine Group Co. Ltd. (1643) vs. iShares MSCI Hong Kong ETF (EWH)

-100%0%100%200%300%400%HK:1643-33.80%EWH+8.92%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 291.60M
Dividend Yield
―
Average Volume (3M)
421.09K
Price to Earnings (P/E)
-5.7
Beta (1Y)
0.53
Revenue Growth
2.06%
EPS Growth
-298.25%
Country
Hong Kong
Employees
189
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Modern Chinese Medicine Group Co. Ltd. Business Overview & Revenue Model

Company Description

As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its...

How the Company Makes Money

The company makes money mainly by selling traditional Chinese medicine products and related healthcare products through its distribution channels. Its revenue model is primarily product-driven: it generates revenue when it delivers finished TCM/propr...

Modern Chinese Medicine Group Co. Ltd. Financial Statement Overview

Summary

The near debt-free balance sheet and steadily growing assets provide financial resilience, but this is outweighed by sharply declining revenue, a move to losses, negative returns, and volatile or negative recent free cash flow.

Income Statement

30Negative

Balance Sheet

80Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue197.74M141.42M214.07M344.07M399.66M360.69M
Gross Profit27.30M22.73M55.20M104.17M170.79M158.43M
EBITDA-12.59M-4.63M33.10M74.75M130.03M117.02M
Net Income-41.67M-13.21M9.67M48.80M87.83M81.78M
Balance Sheet
Total Assets499.10M543.63M540.31M528.53M501.53M395.94M
Cash, Cash Equivalents and Short-Term Investments119.66M229.81M229.67M286.27M282.26M176.09M
Total Debt1.20M69.03K135.00K72.00K393.00K410.00K
Total Liabilities30.79M45.43M56.08M55.64M78.60M58.58M
Stockholders Equity468.31M498.20M484.23M472.89M422.93M337.36M
Cash Flow
Free Cash Flow-126.10M-16.58M-55.32M3.38M114.06M-12.87M
Operating Cash Flow-105.08M4.85M58.98M8.48M125.79M57.60M
Investing Cash Flow-84.87M-35.37M-115.49M-4.19M-11.05M-70.05M
Financing Cash Flow26.28M28.68M-144.00K-326.00K-8.73M115.76M

Modern Chinese Medicine Group Co. Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.47

Price Trends

50DMA0.56Negative
100DMA0.75Negative
200DMA1.33Negative

Market Momentum

MACD-0.05Negative
RSI45.34Neutral
STOCH35.09Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1643, the sentiment is Neutral. The current price of 0.47 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.56, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.34 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1643.

Modern Chinese Medicine Group Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:1643 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0239HK:023986OutperformHKD 738.59M7.3813.59%8.44%10.63%39.44%
HK:0950HK:095068NeutralHKD 618.28M3.718.02%5.50%7.05%22.46%
HK:1666HK:166662NeutralHKD 3.75B10.604.19%7.06%-13.93%-25.30%
HK:0897HK:089759NeutralHKD 406.75M101.390.34%―-8.30%-44.44%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1643HK:164345NeutralHKD 291.60M-5.71-8.62%―2.06%-298.25%
HK:1498HK:149841NeutralHKD 117.69M-3.87-21.66%―-6.71%43.14%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%HK:1643HK:1666HK:0897HK:0950HK:1498HK:0239Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:1643 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:1643Modern Chinese Medicine Group Co. Ltd.0.47-0.22-31.88%
HK:1666Tong Ren Tang Technologies Co Class H3.00-1.46-32.80%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.38-0.08-16.67%
HK:0950Lee's Pharmaceutical Holdings Limited1.01-0.70-40.94%
HK:1498PuraPharm Corp. Ltd.0.22-0.16-42.11%
HK:0239Pak Fah Yeow International Limited2.370.114.83%

Modern Chinese Medicine Group Co. Ltd. Corporate Events

Modern Chinese Medicine Group Ends VIE Structure After China Lifts TCM Manufacturing Curbs

Oct 21, 2026

Modern Chinese Medicine Group Co., Ltd. has announced the termination of its contractual arrangements structure used to control Chengde Yushi Jindan Pharmaceutical Co., Ltd. on the Chinese Mainland. This decision follows regulatory changes in the 202...

Modern Chinese Medicine Swings to Interim Loss Despite Surge in Revenue

Aug 28, 2026

Modern Chinese Medicine Group Co. Ltd. reported an 82.9% jump in revenue to RMB118.5 million for the six months ended 30 June 2026, with gross profit rising 36.4% to RMB22.1 million compared with a year earlier. Despite this top-line growth, the comp...

Modern Chinese Medicine Group Warns of Interim Loss Amid Expansion and R&D Push

Aug 21, 2026

Modern Chinese Medicine Group Co., Ltd. has issued a profit warning for the six months ended 30 June 2026, flagging an expected net loss of approximately RMB25.9 million versus a net profit of about RMB2.5 million a year earlier. The board attributes...

Modern Chinese Medicine Group Sets August Board Meeting for Interim Results and Dividend Review

Aug 13, 2026

Modern Chinese Medicine Group Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider proposing an interim dividend, a decision...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026